Cite
APA Citation
Berinstein, N., Bence-Bruckler, I., Forward, N., Laneuville, P., Mangel, J., Stewart, D., Amitai, I., Klein, G., Pennell, N., Rashedi, I., Roos, K., Bramhecha, Y., & Conlon, R. (n.d.). 356 Baseline PD-L1 expression and tumor immune infiltration is associated with clinical response in patients with r/r DLBCL treated with DPX-Survivac, low-dose cyclophosphamide and pembrolizumab. Journal for immunotherapy of cancer, 8, A217–A218. http://access.bl.uk/ark:/81055/vdc_100144718278.0x000005